《中国糖尿病杂志》官方网站

20

您的位置:首页 > 中国糖尿病杂志 > 2011年 > 6期

天芪降糖胶囊预防2型糖尿病

来自:中国糖尿病资讯网  编辑:lj|点击数:|2011-10-20

天芪降糖胶囊预防2型糖尿病:一项在中国糖耐量减低患者中进行的随机、

双盲、安慰剂对照研究

·糖尿病临床研究·

孙晓方 屈克义 黄汉涛 张茜 石贵昌 茅李莉 仝小林 向红丁 肖新华

基金项目:国家“十一五”科技支撑计划项目(2006BA104A04)

作者单位:中国医学科学院、北京协和医学院、北京协和医院内分泌科、卫生部内分泌重点实验室(孙晓方、张茜、茅李莉、向红丁、肖新华);

湖北省宜昌市夷陵医院(屈克义、黄汉涛、石贵昌);

中国中医科学院广安门医院(仝小林)

通讯作者:肖新华,E-mail:xiaoxinhua@medmail.com.cn

【摘要】 目的 观察天芪降糖胶囊对预防糖耐量减低 (IGT)患者向2型糖尿病(T2DM)发展的效果。 方法 216例IGT患者,随机分为2组,分别口服天芪降糖胶囊(TQ组,110例)和对照组(Con组,106例),观察治疗后血糖变化及转化为正常血糖和T2DM的比例。 结果 天芪降糖胶囊治疗后服糖2h血糖(2hPG)值明显低于基线值(P=0.000),且2hPG下降幅度大于Con组(P<0.005);与Con组相比,天芪降糖胶囊使T2DM发生风险下降56%。 结论 天芪降糖胶囊可显著降低IGT患者向T2DM发展的风险。

doi:10.3969/j.issn.1006-6187.2011.06.010

Tianqi Jiangtang capsule for prevention of type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study in Chinese individuals with impaired glucose tolerance

SUN Xiao-fang, QU Ke-yi, HUANG Han-tao, et al. Department of Endocrinology, Key Laboratory of Ministry of Health, PUMC Hospital, CAMS & PUMC, Beijing 100730, China

Corresponding author:XIAO Xin-hua, E-mail: xiaoxinhua@medmail.com.cn

【Abstract】 Objective To assess whether Tianqi Jiangtang capsule could prevent the development of type 2 diabetes mellitus (T2DM) in high-risk Chinese individuals with impaired glucose tolerance (IGT). Methods In the double-blind, 12-month prospective study,216 IGT subjects from communities of Yichang city in Hubei province were included, IGT was defined by 1999 WHO. These subjects were randomly assigned to Tianqi Jiangtang capsule group (n=110) or placebo group(n=106). OGTT, weight, blood pressure, liver and kidney function, lipids were measured every three months during the follow-up. Treatment was not stopped until participants developed T2DM or euglycemia. Results In Tianqi Jiangtang capsule group, the 2-h postprandial glucose (2hPG) at the end of the study was lower than at baseline(P=0.000). The decrement of 2hPG in Tianqi Jiangtang capsule group was higher than in placebo group (P<0.005). Fasting plasma glucose (FPG) had no significant reduction in both groups. Patients treated with Tianqi Jiangtang capsule had a lower risk of progression to T2DM than did on placebo group,so the risk of T2DM reduced by 56% after Tianqi Jiangtang capsule treatment of IGT. More people in the Tianqi Jiangtang capsule group achieved euglycemia than in the placebo group (61.8% vs 44.3%). Conclusion Tianqi Jiangtang capsule can reduce the development of T2DM in high-risk Chinese individuals with IGT. In the future, Tianqi Jiangtang capsule could be used on prevention of type 2 diabetes mellitus.

【Key words】Tianqi Jiangtang capsule; Impaired glucose tolerance; Diabetes mellitus, type 2

上一篇:江苏省不同糖耐量人群代谢综合征的患病率研究 下一篇:体重及其构成成分对2型糖尿病患者骨量的影响